Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer

• DOI: 10.1126/sciimmunol.ade4656
• Publication Date: 2023-03-10T18:58:05Z
• Authors: Yini Zhu; Yun Zhao; Jiling Wen; Sheng Liu; Tianhe Huang; Ishita Hatial; Xiaoxia Peng; Hawraa Al Janabi; Gang Huang; Jackson Mittlesteadt; Michael Cheng; Atul Bhardwaj; Brandon L. Ashfeld; Kenneth R. Kao; Dean Y. Maeda; Xing Dai; Olaf Wiest; Brian S.J. Blagg; Xuemin Lu; Liang Cheng; Jun Wan; Xin Lu
• Keywords: Urologic Diseases; Male; Aging; Cytotoxic; T-Lymphocytes; Mice, Transgenic; CD8-Positive T-Lymphocytes; Transgenic; Vaccine Related; Mice; Genetics; Tumor Microenvironment; 2.1 Biological and endogenous factors; Animals; Humans; Aetiology; Cancer; Prostate Cancer; Intracellular Signaling Peptides and Proteins; Prostatic Neoplasms; Chromatin; 3. Good health; 5.1 Pharmaceuticals; Immunization; Immunotherapy; Development of treatments and therapeutic interventions; T-Lymphocytes, Cytotoxic

The noninflamed microenvironment in prostate cancer represents a barrier to immunotherapy. Genetic alterations underlying cancer cell–intrinsic oncogenic signaling are increasingly appreciated for their role in shaping the immune landscape. Recently, we identified Pygopus 2 ( PYGO2 ) as the driver oncogene for the amplicon at 1q21.3 in prostate cancer. Here, using transgenic mouse models of metastatic prostate adenocarcinoma, we found that Pygo2 deletion decelerated tumor progression, diminished metastases, and extended survival. Pygo2 loss augmented the activation and infiltration of cytotoxic T lymphocytes (CTLs) and sensitized tumor cells to T cell killing. Mechanistically, Pygo2 orchestrated a p53/Sp1/Kit/Ido1 signaling network to foster a microenvironment hostile to CTLs. Genetic or pharmacological inhibition of Pygo2 enhanced the antitumor efficacy of immunotherapies using immune checkpoint blockade (ICB), adoptive cell transfer, or agents inhibiting myeloid-derived suppressor cells. In human prostate cancer samples, Pygo2 expression was inversely correlated with the infiltration of CD8 + T cells. Analysis of the ICB clinical data showed association between high PYGO2 level and worse outcome. Together, our results highlight a potential path to improve immunotherapy using Pygo2-targeted therapy for advanced prostate cancer.